Positive results from Opthea’s Phase 1b trial of sozinibercept combination therapy in diabetic macular oedema (DMO) have been published in the peer-reviewed journal Translational

A new study has found a “clear association” between concentration problems and fatigue severity in patients with visual impairment (VI).

Centre for Eye Research Australia start-up Mirugen has been granted AU$1.92 million for its work developing a treatment harnessing the regenerative power of the

Obstructive sleep apnoea (OSA) could be an underappreciated yet important modifiable risk factor for neovascular age-related macular degeneration (nAMD), Australian researchers have found.